Goldman Sachs
BBP icon

Goldman Sachs’s Virtus Biotech ETF BBP Stock Holding History

Goldman Sachs’s Portfolio BBP Stock Details BBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,342
Closed -$210K – 6025
2024
Q3 		$210K Sell
3,342
-2,603
-44% -$162K ﹤0.01% 5437
2024
Q2 		$349K Sell
5,945
-500
-8% -$27.9K ﹤0.01% 5018
2024
Q1 		$365K Buy
+6,445
New +$376K ﹤0.01% 4886

Other funds holding BBP

CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JCM
Jag Capital Management St Louis, Missouri $889M AUM 42.63% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Goldman Sachs's BBP Position: Q4 2024 in Review

Goldman Sachs sold out of Virtus Biotech ETF (BBP) in Q4 2024, closing a stake of 3,342 shares — an estimated $210K sold.

Goldman Sachs first reported a position in BBP in Q1 2024 and held it in 3 quarters. The position peaked at $365K in Q1 2024. 13 funds tracked by Wall St. Rank hold BBP as of Q4 2024.

  • Goldman Sachs reported no remaining Virtus Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • Goldman Sachs sold 3,342 Virtus Biotech ETF shares in Q4 2024, an estimated $210K.
  • Goldman Sachs first reported a position in Virtus Biotech ETF in Q1 2024 and held it in 3 quarters.
  • Goldman Sachs's Virtus Biotech ETF position peaked at $365K in Q1 2024.
  • 13 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q4 2024.

Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.